Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,735

“This is kind of a nice bookend to 16 years of research,” says Deisseroth, a neuroscientist and bioengineer at Stanford University. “It took years and years for us to sort out how to make it work.”

“The result is described this month in the journal Nature Biotechnology.”

“Optogenetics involves genetically engineering animal brains to express light-sensitive proteins—called opsins—in the membranes of neurons.”

Optogenetics can now control neural circuits at unprecedented depths within living brain tissue without surgery.

Read more | >

Article from CNN. I didn’t expect drones would have so much impact all over the world.

It’s good to see that it’s helping people in Africa.

Drones have been transforming logistics in parts of Africa, especially for the delivery of medical products.

CNN’s Eleni Giokos examines how this technology has been serving the needs of rural communities in Ghana, and what’s next for supply chains using drones during uncertain times.

Read more | >

“In a breakthrough study published on February 19th in Nature Biomedical Engineering, researchers connected neural dust implants reduced to 1.7 cubic millimeters to rat sciatic nerves. The implanted device, called the StimDust system, consisted of very few components, which will be scaled down for future applications. A piezoceramic ultrasonic transducer generated power allowing for wireless communication and stimulation. A capacitor stored any excess energy generated from ultrasonic beams. Bipolar stimulating electrodes directly interfaced with the nerve while a cuff attached to a small circuit-board allowed the device to adhere physically to the nerve. These components were sufficient to generate or record nerve-impulses. In anesthetized rodents, they elicited muscular contractions with the StimDust system.”

While Neuralink, Elon Musk’s startup-venture focused on creating a brain-computer interface, garners lots of coverage in the biotechnology space, other bioelectronics ventures continue innovating in this space.

iota Biosciences, a spin-off company from UC Berkley formed in 2017, made news two years ago by securing $15 million in Series A funding and again last year announcing a partnership with Astellas Pharma Inc. Bolstered by studies in rodents, iota Biosciences advances towards their vision. In a press release on their partnership, founders Jose Carmena and Michel Maharbiz commented:

We envision a future in which our ultra-small implantable devices will be used in combination with, or as an alternative to, conventional diagnostics and therapies. Through our collaboration with Astellas, we expect to make our innovative technologies available to patients around the world.

Carmena and Maharbiz are right on track, winning the prestigious 2017 McKnight Technological Innovation in Neuroscience Award. While electric stimulation devices for the heart, cochlea and brain already exist, Carmenas and Maharbiz recognized the key limitations of existing technologies.

Read more | >

SpaceX launched its first crewed mission to ISS in May this year. The company demonstrated its spacecraft is safe and reliable to carry humans to space and back. Axiom’s space tourist mission with SpaceX is scheduled to be a 10-day journey that will launch civilians aboard Crew Dragon to the space station atop a Falcon 9 rocket. The space tourists will stay at ISS for 8 days, where they will experience microgravity and amazing views of our planet.

SpaceX’s first private civilian flight will carry three Axiom customers who will fly alongside former NASA Astronaut Michael Lopez-Alegria, he will be commander during the mission. Earlier this year, NASA and SpaceX announced Hollywood actor Tom Cruise will film a movie at the space station and fly aboard Crew Dragon. Then, reports surfaced about Cruise and his film production agency working with Axiom is responsible for providing ‘training, mission planning, hardware development, life support, medical support, crew provisions, hardware and safety certifications, on-orbit operations and overall mission management.’ However, Axiom has not officially disclosed who their private passengers will be on their first mission in collaboration with SpaceX.

Read more | >

Rock-climb without fear. Play a symphony in your head. See radar with superhuman vision. Discover the nature of consciousness. Cure blindness, paralysis, deafness, and mental illness. Those are just a few of the applications that Elon Musk and employees at his four-year-old neuroscience company Neuralink believe electronic brain-computer interfaces will one day bring about.

None of these advances are close at hand, and some are unlikely to ever come about. But in a “product update” streamed over YouTube on Friday, Musk, also the founder of SpaceX and Tesla Motors, joined staffers wearing black masks to discuss the company’s work toward an affordable, reliable brain implant that Musk believes billions of consumers will clamor for in the future.

“In a lot of ways,” Musk said, “It’s kind of like a Fitbit in your skull, with tiny wires.”

Read more | >

U.S. company can keep hosting vast coronavirus-related project but must protect French citizens’ health data from American government, court rules.

A French court has ruled that Microsoft Corp. can continue hosting a government-run project aggregating citizens’ anonymous health data to use for AI-based research, but must guarantee no data will be sent to the U.S. or be shared with American intelligence authorities.

The ruling, handed down last week, contradicts the stance of France’s data protection authority, which told the court this month that any U.S. cloud provider could be forced to comply with U.S. surveillance laws and should therefore not be allowed to host sensitive health data. The regulator’s opinion could provide clues for other companies handling such data, legal experts say.

Companies are wrestling with tricky decisions about moving their data from the European Union to the U.S., following a court decision this summer that required personal data transferred there to include special guarantees against surveillance by the American government.

Read more | >

In the 2013 science fiction film “Elysium” starring Matt Damon, Earth’s wealthiest 0.01% move to the ultimate gated community, a luxurious orbiting space colony, leaving a poverty-stricken humanity to fend for themselves on a ravaged planet.

Interestingly, it is indeed some of today’s 0.1% who are leading the way into space to build communities beyond Earth. However, quite the opposite of the movie, their goals are of the highest order, from democratizing access to space by lowering costs, to creating new products and ideas, to helping save the planet and opening space to future generations.

Yet, given the effects of the coronavirus pandemic, social justice and green movements, even as entrepreneurs like Elon Musk, Jeff Bezos and Richard Branson spend billions to support a human breakout into space, there is a backlash building that holds these projects as icons of extravagance — even as their work may help save the Earth. This is the “Elysium effect.”

Read more | >